Premium
Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies
Author(s) -
Bagrodia Shubha,
Smeal Tod,
Abraham Robert T.
Publication year - 2012
Publication title -
pigment cell and melanoma research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.618
H-Index - 105
eISSN - 1755-148X
pISSN - 1755-1471
DOI - 10.1111/pcmr.12007
Subject(s) - acquired resistance , cancer research , drug resistance , melanoma , medicine , lung cancer , kinase , cancer , targeted therapy , small molecule , drug , biology , bioinformatics , oncology , pharmacology , microbiology and biotechnology , genetics
Summary Cancer drugs that target pivotal signaling molecules required for malignant cell survival and growth have demonstrated striking antitumor activities in appropriately selected patient populations. Unfortunately, however, therapeutic responses are often of limited duration, typically 6–12 months, because of emergence of drug‐resistant subclones of tumor cells. In this review, we highlight several of the mechanisms of emergent resistance to several kinase‐targeted small molecule therapies used in melanoma, non‐small cell lung cancer ( NSCLC ) and other solid tumors as illustrative examples. We discuss the implications of these findings for the development of new treatment strategies to delay or prevent the onset of drug resistance.